Publications in collaboration with researchers from Università di Perugia (7)

2022

  1. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

    The Lancet Haematology, Vol. 9, Núm. 2, pp. e98-e110

  2. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798

2020

  1. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573

2018

  1. Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis

    JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397

2017

  1. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

    British Journal of Haematology, Vol. 178, Núm. 4, pp. 571-582

2013

  1. Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials

    Haematologica, Vol. 98, Núm. 6, pp. 980-987